CTFG
MRNA icon

Capstone Triton Financial Group’s Moderna MRNA Stock Holding History

Capstone Triton Financial Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,683
Closed -$319K – 111
2024
Q2 		$319K Sell
2,683
-588
-18% -$74.4K 0.22% 84
2024
Q1 		$349K Sell
3,271
-261
-7% -$26.3K 0.25% 84
2023
Q4 		$351K Sell
3,532
-2,081
-37% -$175K 0.26% 82
2023
Q3 		$580K Sell
5,613
-44
-0.8% -$4.91K 0.42% 66
2023
Q2 		$687K Sell
5,657
-110
-2% -$14.7K 0.47% 66
2023
Q1 		$886K Sell
5,767
-638
-10% -$105K 0.67% 59
2022
Q4 		$1.15M Sell
6,405
-395
-6% -$64.6K 0.92% 38
2022
Q3 		$804K Sell
6,800
-922
-12% -$140K 0.69% 48
2022
Q2 		$1.3M Sell
7,722
-150
-2% -$21.4K 0.99% 35
2022
Q1 		$1.12M Buy
+7,872
New +$1.33M 0.78% 39
2021
Q4 		– Sell
-7,511
Closed -$2.63M – 111
2021
Q3 		$2.63M Buy
7,511
+286
+4% +$105K 1.58% 16
2021
Q2 		$1.7M Buy
7,225
+900
+14% +$161K 1.04% 30
2021
Q1 		$828K Buy
6,325
+3,641
+136% +$528K 0.55% 45
2020
Q4 		$280K Buy
+2,684
New +$272K 0.17% 87

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capstone Triton Financial Group's MRNA Position: Q3 2024 in Review

Capstone Triton Financial Group sold out of Moderna (MRNA) in Q3 2024, closing a stake of 2,683 shares — an estimated $319K sold.

Capstone Triton Financial Group first reported a position in MRNA in Q4 2020 and held it in 14 quarters. The position peaked at $2.63M in Q3 2021. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Capstone Triton Financial Group reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Capstone Triton Financial Group sold 2,683 Moderna shares in Q3 2024, an estimated $319K.
  • Capstone Triton Financial Group first reported a position in Moderna in Q4 2020 and held it in 14 quarters.
  • Capstone Triton Financial Group's Moderna position peaked at $2.63M in Q3 2021.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Capstone Triton Financial Group's 13F filing for Q3 2024, filed 25 Oct 2024.